Skip to main content
. 2019 Feb 20;38:90. doi: 10.1186/s13046-019-1087-1

Fig. 5.

Fig. 5

The Dose Reduction Index (DRI) for each drug reported in the table resulted > 1, as the dose to obtain the 50% Fractional Effect (IC50) resulted reduced upon the association of the three drugs: a J82, (RRx-001 + P5091 + Olaparib): RRx-001 [IC50 4.1 μM vs 1.25 μM]; P5091 [IC50 7.9 μM vs 1.5 μM]; Olaparib [IC50 40.04 μM vs 6.71 μM]; b T24, (RRx-001 + P5091 + Olaparib): RRx-001 [IC50 3.84 μM vs 1.25 μM]; P5091 [IC50 4.21 μM vs 1.5 μM]; Olaparib [IC50 57.63 μM vs 3.56 μM]; c 5637, (RRx-001 + P5091 + Olaparib): RRx-001 [IC50 4.28 μM vs 1.25 μM]; P5091 [IC50 4.90 μM vs 1.5 μM]; Olaparib [IC50 25.61 μM vs 1.99 μM]; d KU-19-19, (RRx-001 + P5091 + Olaparib): RRx-001 [IC50 3.62 μM vs 1.25 μM]; P5091 [IC50 4.83 μM vs 1.5 μM]; Olaparib [IC50 22.25 μM vs 2.29 μM]; e Sketch of RRx-001 contribution to DNA damage